Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

Compounding of this drug is currently illegal under federal law in the U.S. However, buzz around the drug’s effectiveness has ...

The buzz around weight-loss drugs has never been louder or more exciting, especially when it comes to a brand new option called retatrutide or “reta”—stuff so powerful it’s basically threatening to ...

You’ve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now there’s a new kid on the weight ...

Some people taking the investigational medication retatrutide lost an average of 30 percent of their body weight in about 2 years. The medication offers weight reduction on par with bariatric surgery.

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint. iiThe extension period enrolled 532 participants with BMI ≥35 at baseline who had completed the main 80-week study ...

iPercent change in the WOMAC pain subscale score and percent change in the WOMAC physical function subscale score were not pre-specified and were estimated from a post-hoc analysis.iiNot controlled ...

Retatrutide weight loss drug trials recorded 28.3% average body weight loss, outpacing surgery and all existing GLP-1 ...